Makino H, Kuzuna S, Naka T, Saijo T, Maki Y
Biology Laboratories, Takeda Chemical Industries, Ltd., Osaka, Japan.
Agents Actions. 1988 Dec;25(3-4):385-93. doi: 10.1007/BF01965047.
The antiinflammatory, analgesic, and antipyretic activities of methyl 7-butyl-4,5,6,7-tetrahydro-3-methylamino-4,6-dioxo-5-propyl-2H-pyrazolo[ 3, 4-d]pyrimidine-2-carboxylate (AA-2379), a novel non-acidic agent, were examined. 1. AA-2379 had a potent antiinflammatory activity; 3-25 mg/kg, p.o. of the compound inhibited rat carrageenin-, bradykinin-, trypsin-, formalin-, dextran-, and nystatin-induced paw edema; mouse traumatic edema; and rat croton oil pouch inflammation by about 30%. The compound at 25-50 mg/kg, p.o. also inhibited the vascular permeability induced by histamine, serotonin, and bradykinin. 2. AA-2379 had an analgesic activity; the ID50 values in mouse phenylquinone-induced writhing were 10.1 mg/kg, p.o. and the compound at 12.5 mg/kg, p.o. inhibited dog urate arthritis. 3. AA-2379 at 3-10 mg/kg, p.o. showed antipyretic activity in febrile rats and rabbits. 4. AA-2379, at 500 mg/kg, p.o. was not ulcerogenic in rats. 5. These data show that AA-2379 is more active than non-acidic antiinflammatory agents, such as tiaramide and aminopyrine.
对新型非酸性药物7-丁基-4,5,6,7-四氢-3-甲氨基-4,6-二氧代-5-丙基-2H-吡唑并[3,4-d]嘧啶-2-羧酸甲酯(AA-2379)的抗炎、镇痛和解热活性进行了研究。1. AA-2379具有强效抗炎活性;口服该化合物3-25mg/kg可抑制大鼠角叉菜胶、缓激肽、胰蛋白酶、福尔马林、右旋糖酐和制霉菌素诱导的足爪肿胀;小鼠创伤性肿胀;以及大鼠巴豆油袋炎症,抑制率约为30%。口服25-50mg/kg的该化合物还可抑制组胺、5-羟色胺和缓激肽诱导的血管通透性。2. AA-2379具有镇痛活性;在小鼠苯醌诱导的扭体实验中,其半数抑制剂量(ID50)值为口服10.1mg/kg,口服12.5mg/kg的该化合物可抑制犬尿酸盐性关节炎。3. 口服3-10mg/kg的AA-2379在发热大鼠和家兔中显示出解热活性。4. 口服500mg/kg的AA-2379对大鼠无致溃疡作用。5. 这些数据表明,AA-2379比非酸性抗炎药如替拉米特和氨基比林更具活性。